Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Novel fusion proteins to target PD-L1 in HPV associated cancers

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 195
Rating:

Dr James Gulley - Center for Cancer Research, Washington, USA

Dr Gulley speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the phase I study of M7824 for patients with HPV associated cancers.

He comments on how this could change clinical practice in certain settings and highlights the importance of using novel fusion proteins to target PD-L1.

For more on this study watch Dr Strauss discuss it further with ecancer here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
 

Related videos

follow us

Breast Cancer CDK 4/6


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence